To the Editor We read the study by Goldstein et al1 with great interest. Based on secondary analysis of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM) 3 trial showing superior outcomes with HeartMate 3 pumps, the authors challenge the utility of more than 2-decades-old predefined indications for left ventricular assist device (LVAD) therapy, namely, bridge to transplant, bridge to candidacy, and destination therapy. They advocate for a single preimplant indication, namely, extend survival and quality of life in those with medically refractory heart failure. We are not completely convinced by this idea.
Pal N, Nelson M, Butterworth J. Redefining Left Ventricular Assist Device Indications and Strategies. JAMA Cardiol. 2021;6(1):119. doi:10.1001/jamacardio.2020.4303
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: